

ENANTA PHARMACEUTICALS INC
Form 4
March 05, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
TVM V LIFE SCIENCE
VENTURES GMBH & CO KG

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS
INC [ENTA]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

C/O TVM CAPITAL
CROUP, OTTOSTRASSE 4

(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
03/03/2014

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

MUNICH, 2M 80333

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
X Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	03/03/2014		S	1,402	D	\$ 38.8337 (1)	351,635 D (2)
Common Stock	03/03/2014		S	1,874	D	\$ 38.8337 (1)	469,929 D (3)
Common Stock	03/03/2014		S	5,795	D	\$ 38.8337 (1)	1,453,414 D (4)
Common	03/04/2014		S	66,506	D	\$	285,129 D (2)

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

Stock					38.8155			
					<u>(5)</u>			
					\$			
Common Stock	03/04/2014		S	88,877	D	38.8155	381,052	D <u>(3)</u>
						<u>(5)</u>		
						\$		
Common Stock	03/04/2014		S	274,880	D	38.8155	1,178,534	D <u>(4)</u>
						<u>(5)</u>		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 5)
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V	(A)	(D)

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

TVM V LIFE SCIENCE VENTURES GMBH & CO KG
C/O TVM CAPITAL CROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

TVM V Life Science Ventures Management GmbH & Co. KG
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

TVM IV GMBH & CO KG
C/O TVM CAPITAL GROUP

X

OTTOSTRASSE 4
MUNICH, 2M 80333

TVM IV Management GmbH & Co. KG
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

TVM MEDICAL VENTURES GMBH & CO KG
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

TVM Capital GmbH
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

Birner Hubert
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

Fischer Stefan
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

Goll Alexandra
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

SCHUHSLER HELMUT
C/O TVM CAPITAL GROUP
OTTOSTRASSE 4
MUNICH, 2M 80333

X

Signatures

/s/ Josef Moosholzer, Managing Limited Partner of TVM V Life Science Ventures
Management GmbH & Co. KG, managing limited partner of TVM V Life Science Ventures
GmbH & Co. KG

03/05/2014

__Signature of Reporting Person

Date

/s/ Josef Moosholzer, Managing Limited Partner of TVM V Life Science Ventures
Management GmbH & Co. KG

03/05/2014

__Signature of Reporting Person

Date

/s/ Josef Moosholzer, Managing Limited Partner of TVM IV Mangement GmbH & Co. KG,
managing limited partner of TVM IV GmbH & Co. KG

03/05/2014

__Signature of Reporting Person

Date

/s/ Josef Moosholzer, Managing Limited Partner of TVM IV Mangement GmbH & Co. KG

03/05/2014

__Signature of Reporting Person

Date

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

/s/ Josef Moosholzer, Managing Limited Partner of TVM Capital GmbH, general partner of TVM Medical Ventures GmbH & Co. KG	03/05/2014
__Signature of Reporting Person	Date
/s/ Josef Moosholzer, Managing Limited Partner of TVM Capital GmbH	03/05/2014
__Signature of Reporting Person	Date
/s/ Stefan Fischer by power of Attorney for Hubert Birner	03/05/2014
__Signature of Reporting Person	Date
/s/ Stefan Fischer	03/05/2014
__Signature of Reporting Person	Date
/s/ Stefan Fischer by power of Attorney for Alexandra Goll	03/05/2014
__Signature of Reporting Person	Date
/s/ Stefan Fischer by power of Attorney for Helmut Schuhsler	03/05/2014
__Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.80 to \$39.03, inclusive. Each Reporting Person undertakes to provide to Enanta Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(2) The shares are directly held by TVM Medical Ventures GmbH & Co. KG ("Medical Ventures"), the general partner of which is TVM Capital GmbH ("TVM Capital"), for which Alexandra Goll ("Goll") and Helmut Schuhsler ("Schuhsler"), each members of the investment committee of TVM Capital, share voting and investment authority over the shares held by Medical Ventures with the other members of the investment committee. Each of TVM Capital, Goll and Schuhsler disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

(3) The shares are directly held by TVM IV GmbH & Co. KG ("TVM IV"), the managing limited partner of which is TVM IV Management GmbH & Co. KG ("TVM IV Management"), for which Goll and Schuhsler, each members of the investment committee of TVM IV Management, share voting and investment authority over the shares held by TVM IV with the other members of the investment committee. Each of TVM IV Management, Goll and Schuhsler disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

(4) The shares are directly held by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"), the managing limited partner of which is TVM V Life Science Ventures Management GmbH & Co. KG ("TVM V Management"), for which Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), Goll and Schuhsler, each members of the investment committee of TVM V Management, share voting and investment authority over the shares held by TVM V. Each of TVM V Management, Birner, Fischer, Goll and Schuhsler disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.80 to \$39.62, inclusive. Each Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.